MODERN LABORATORY APPROACHES IN THE DIAGNOSIS OF CMV INFECTION IN IMMUNOCOMPROMISED PATIENTS

Cover Page

Cite item

Abstract

Abstract. High susceptibility of immunocomromised human to infection (especially transplant recipients) is influenced by poor ability to combat it due to impaired cellmediated immunity plus high vulnerability to perturbations in the environment. Special considerations regarding infection in transplant recipients and particular approaches in laboratory diagnostics are based on profound analysis of the nature of viral infection in this population. In this article the modern knowledge about viral infections and laboratory diagnostic methods, particularly regarding CMV infection, in immunocompromised patients are discussed. 

About the authors

E. Iu. Padalko

Ghent University Hospital, Ghent

Author for correspondence.
Email: okubar@list.ru

PhD, Chief, Laboratory of Clinical Virology, Ghent University Hospital; Professor of Virology, Hasselt University

Belgium

References

  1. Baldanti F., Lilleri D., Gerna G. Human cytomegalovirus load measurement and its applications for pre-emptive therapy in patients undergoing hematopoietic stem cell transplantation. Hematol. Oncol., 2008, vol. 26 (3), pp. 123–130.
  2. Boeckh M., Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood., 2009, vol. 113 (23), pp. 5711–5719.
  3. Fishman J.A., Rubin R.H. Infection in organ-transplant recipients. N. Engl. J. Med., 1998, vol. 338 (24), pp. 1741–1751.
  4. Gerna G., Baldanti F., Lilleri D., Parea M., Torsellini M., Castiglioni B., Vitulo P., Pellegrini C., Viganò M., Grossi P., Revello M.G. Human cytomegalovirus pp67 mRNAemia versus pp65 antigenemia for guiding preemptive therapy in heart and lung transplant recipients: a prospective, randomized, controlled, open-label trial. Transplantation, 2003, vol. 15;75 (7), pp. 1012–1019.
  5. Griffiths P., Whitley R., Snydman D.R., Singh N., Boeckh M.; International Herpes Management Forum. Contemporary management of cytomegalovirus infection in transplant recipients: guidelines from an IHMF workshop, 2007. Herpes, 2008, vol. 15 (1), pp. 4–12.
  6. Koidl C., Bozic M., Marth E., Kessler H.H. Detection of CMV DNA: is EDTA whole blood superior to EDTA plasma? J. Virol. Methods, 2008, vol. 154 (1–2), pp. 210–212.
  7. Kotton C.N., Kumar D., Caliendo A.M., Asberg A., Chou S., Snydman D.R., Allen U., Humar A.; Transplantation Society International CMV Consensus Group. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation, 2010, vol. 89 (7), pp. 779–795.
  8. Limaye A.P., Corey L., Koelle D.M., Davis C.L., Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet, 2000, vol. 356 (9230), pp. 645–649.
  9. Linden P.K. Approach to the immunocompromised host with infection in the intensive care unit. Infect. Dis. Clin. North Am., 2009, vol. 23 (3), pp. 535–556.
  10. Mañez R., St George K., Linden P., Martin M., Kusne S., Grossi P., Ho M., Rinaldo C. Diagnosis of cytomegalovirus infections by shell vial assay and conventional cell culture during antiviral prophylaxis. J. Clin. Microbiol., 1994, vol. 32 (11), pp. 2655–2659.
  11. Paya C., Humar A., Dominguez E., Washburn K., Blumberg E., Alexander B., Freeman R., Heaton N., Pescovitz M.D.; Valganciclovir Solid Organ Transplant Study Group. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant., 2004, vol. 4 (4), pp. 611–620.
  12. Razonable R.R., Emery V.C.; 11th Annual Meeting of the IHMF [International Herpes Management Forum]. Management of CMV infection and disease in transplant patients. 27–29 February 2004. Herpes, 2004, vol. 11 (3), pp. 77–86.
  13. Razonable R.R. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am. J. Health Syst. Pharm., 2005, vol. 15;62 (8 suppl. 1), pp. S7–13.
  14. Riise G.C., Andersson R., Bergström T., Lundmark A., Nilsson F.N., Olofsson S. Quantification of cytomegalovirus DNA in BAL fluid: a longitudinal study in lung transplant recipients. Chest, 2000, vol. 118 (6), pp. 1653–1660.
  15. Seed C.R., Piscitelli L.M., Maine G.T., Lazzarotto T., Doherty K., Stricker R., Stricker R., Iriarte B., Patel C. Validation of an automated immunoglobulin G-only cytomegalovirus (CMV) antibody screening assay and an assessment of the risk of transfusion transmitted CMV from seronegative blood. Transfusion, 2009, vol. 49 (1), pp. 134–145.
  16. Tang W., Elmore S.H., Fan H., Thorne L.B., Gulley M.L. Cytomegalovirus DNA measurement in blood and plasma using Roche LightCycler CMV quantification reagents. Diagn. Mol. Pathol., 2008, vol. 17 (3), pp. 166–173.
  17. Weber B., Fall E.M., Berger A., Doerr H.W. Screening of blood donors for human cytomegalovirus [HCMV] IgG antibody with an enzyme immunoassay using recombinant antigens. J. Clin. Virol., 1999, vol. 14 (3), pp. 173–181.
  18. Westall G.P., Michaelides A., Williams T.J., Snell G.I., Kotsimbos T.C. Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients. J. Infect. Dis., 2004, vol. 190 (6), pp. 1076–1083.

Copyright (c) 2014 Padalko E.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 64788 от 02.02.2016.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies